Free Trial

Extendicare Inc. (TSE:EXE) Given Average Rating of "Buy" by Brokerages

Extendicare logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts give Extendicare a consensus "Buy" rating (5 buys, 1 strong buy) with an average 12‑month price target of C$29.38 and multiple recent upgrades pushing targets as high as C$34.50.
  • Shares recently traded at C$28.33 (one‑year high C$29.99) after reporting C$0.29 EPS for the quarter, and the company declared a monthly dividend of C$0.0441 per share (ex‑dividend April 30) implying a ~1.9% yield.
  • MarketBeat previews top five stocks to own in May.

Shares of Extendicare Inc. (TSE:EXE - Get Free Report) have received a consensus recommendation of "Buy" from the six brokerages that are presently covering the stock, MarketBeat Ratings reports. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is C$29.38.

Several research firms recently commented on EXE. TD Securities upgraded Extendicare from a "hold" rating to a "buy" rating and lifted their price target for the stock from C$19.00 to C$32.00 in a research report on Monday, April 6th. Desjardins set a C$34.50 price target on Extendicare and gave the stock a "buy" rating in a research report on Wednesday. BMO Capital Markets lifted their price target on Extendicare from C$24.00 to C$30.00 in a research report on Monday, March 2nd. National Bank Financial boosted their target price on Extendicare from C$24.50 to C$29.00 and gave the company an "outperform" rating in a research report on Thursday, February 5th. Finally, Canadian Imperial Bank of Commerce boosted their target price on Extendicare from C$22.00 to C$32.00 in a research report on Thursday, April 2nd.

Get Our Latest Analysis on EXE

Extendicare Stock Performance

Shares of TSE EXE traded up C$0.35 during midday trading on Wednesday, hitting C$28.33. 179,914 shares of the stock traded hands, compared to its average volume of 315,798. Extendicare has a one year low of C$12.12 and a one year high of C$29.99. The firm has a 50-day moving average of C$26.63 and a two-hundred day moving average of C$22.36. The firm has a market capitalization of C$2.68 billion, a P/E ratio of 25.45 and a beta of 1.18. The company has a debt-to-equity ratio of 91.85, a quick ratio of 0.98 and a current ratio of 1.37.

Extendicare (TSE:EXE - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported C$0.29 EPS for the quarter. Extendicare had a return on equity of 47.65% and a net margin of 5.82%.The company had revenue of C$462.03 million for the quarter. On average, equities analysts forecast that Extendicare will post 0.6134729 EPS for the current fiscal year.

Extendicare Dividend Announcement

The business also recently declared a monthly dividend, which will be paid on Friday, May 15th. Stockholders of record on Friday, May 15th will be paid a dividend of $0.0441 per share. This represents a c) annualized dividend and a dividend yield of 1.9%. The ex-dividend date of this dividend is Thursday, April 30th. Extendicare's payout ratio is currently 44.92%.

About Extendicare

(Get Free Report)

Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.

Featured Stories

Analyst Recommendations for Extendicare (TSE:EXE)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Extendicare Right Now?

Before you consider Extendicare, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.

While Extendicare currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

5G Stocks: The Path Forward is Profitable Cover

Click the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines